Form 4: HealthEquity EVP Boosts Stake via RSU Vesting

HealthEquity's EVP and General Counsel, Delano Ladd, increased direct beneficial ownership through the vesting and grant of restricted stock units.

Summary

• Delano Ladd, Executive Vice President and General Counsel of HealthEquity, Inc. (HQY), reported changes in his beneficial ownership of common stock.
• On March 25, 2026, Ladd acquired 15,157 shares of common stock through a restricted stock unit (RSU) grant at a price of $0.
• These 15,157 RSUs are scheduled to vest 25% on April 1, 2027, with the remaining 75% vesting at 6.25% on the first day of each calendar quarter for the subsequent twelve calendar quarters.
• Additionally, on March 25, 2026, Ladd acquired 20,451 shares of common stock from restricted stock units that vested on that date, also at a price of $0.
• Following these transactions, Delano Ladd's direct beneficial ownership of HealthEquity common stock increased to 108,848 shares.
• The reported transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive compensation practices and a modest increase in insider alignment, without indicating any significant operational or strategic shifts.

Positives

• Increased insider ownership by a key executive (Delano Ladd's direct beneficial ownership rose to 108,848 shares), which can align management interests with shareholders.
• The transactions were executed under a Rule 10b5-1(c) plan, indicating pre-scheduled compensation and not a discretionary market purchase.

Future Outlook

The vesting schedule for the 15,157 restricted stock units indicates future share grants, with 25% vesting on April 1, 2027, and 6.25% quarterly thereafter for twelve quarters, providing a long-term incentive for the executive.

Industry Context

StockSavvy.ai notes that insider acquisitions through RSU vesting are a standard component of executive compensation packages across various industries, including healthcare technology. This practice aims to align executive incentives with the long-term performance and shareholder value of the company.

Comparison to Industry Standards

• This transaction reflects a common executive compensation practice involving Restricted Stock Units (RSUs), which is prevalent across publicly traded companies, particularly in growth-oriented sectors like healthcare technology.
• Similar compensation structures are observed at comparable companies such as Teladoc Health (TDOC) or CVS Health (CVS), where executives receive equity awards that vest over time to incentivize long-term performance and retention.

Stakeholder Impact

• Shareholders: Increased insider ownership may be viewed positively as it further aligns executive interests with shareholder value creation.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• Future vesting of 15,157 restricted stock units, with 25% on April 1, 2027, and 6.25% quarterly thereafter for twelve quarters.

Key Dates

Recommendation

This Form 4 reports routine executive compensation through RSU grants and vesting, which is an expected event and does not provide new fundamental information to warrant a change in investment thesis. The increase in insider ownership is a minor positive, but not significant enough to alter a 'hold' stance based solely on this filing.

Keywords

HealthEquity, HQY, Delano Ladd, Insider Transaction, Form 4, Restricted Stock Units, RSU, Beneficial Ownership, Executive Compensation, Stock Grant